Aplidine

SKU: orb1297925

Description

Aplidine is a potent antiviral agent against SARS-CoV-2 (IC90 = 0.88 nM) and an anti-cancer compound targeting EEF1A2 (Kd = 80 nM). Its applications span oncology and virology research, with studies demonstrating activity in both in vitro cellular assays and in vivo preclinical models.

Research Area

Cell Biology, Infectious Disease & Virology, Molecular Biology

Images & Validation

−

Key Properties

−

CAS Number	137219-37-5
MW	1110.34
Purity	99.86%
Formula	C₅₇H₈₇N₇O₁₅
SMILES	[H][C@@]12CCCN1C(=O)[C@H](CC(C)C)NC(=O)[C@@H](C)C(=O)[C@@H](OC(=O)C[C@H](O)[C@]([H])(NC(=O)[C@@H](NC(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H]1CCCN1C(=O)C(C)=O)[C@@H](C)OC(=O)[C@H](Cc1ccc(OC)cc1)N(C)C2=O)[C@@H](C)CC)C(C)C
Target	DNA/RNA Synthesis,SARS-CoV
Solubility	10% DMSO+90% Corn Oil:3.3 mg/mL (2.97 mM);DMSO:50 mg/mL (45.03 mM)

Bioactivity

−

Target IC50	SARS-CoV-2:0.88 nM(IC90)\|eEF1A2:80 nM(Kd)
In Vivo	In BALB/c mice expressing human ACE2, Aplidine significantly reduced SARS-CoV-2 infection. 0.3 mg/kg Aplidine group results in a reduction of nearly 2 log units in SARS-CoV-2 viral titers in the lungs, and the 1 mg/kg group leads to a reduction of 1.5 log units. Read more...
In Vitro	In hACE2-293T cells, Aplidine exhibits anti–SARS-CoV-2 activity with an IC90 of 0.88 nM. In an established model of human pneumocyte-like cells, Aplidine inhibits SARS-CoV-2 replication with an IC90 of 3.14 nM and a selectivity index of 40.4. Aplidine (20 nM; 1 h) induces a dose-dependent decrease in VEGF secretion in MOLT-4 cells. Aplidine (20 nM; 1 h) does not result in significant inhibition of VEGF-R1 mRNA in normal endothelial cells, which do express VEGFR-1 but do not secrete VEGF. Read more...

Storage & Handling

−

Storage	store at low temperature \| Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice/Shipping at ambient temperature.
Expiration Date	12 months from date of receipt.
Disclaimer	For research use only

Alternative Names

−

DNASynthesis, DNA Synthesis, DNA/RNA Synthesis, COVID-19, advanced cancer, Advanced Malignancies, Aplidine, Antiviral, anticancer, infection, inhibit, Inhibitor, MOLT-4, Plitidepsin, Leukemia, EEF1A2, SARS-CoV, SARS-CoV-2, SARS coronavirus, SARSCoV, RNA Synthesis, RNASynthesis, VEGF

Quality Guarantee

Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our Terms & Conditions and Buying Guide. Contact us at support@biorbyt.com.

Compound Identifiers

PubChem CID

9812534 ↗

Key Properties

−

No computed properties available.

Documents Download

Datasheet

Product Information

Download

Request a Document

Protocol Information

Find More Protocols

Aplidine (orb1297925)

Based on 0 reviews

Participating in our Biorbyt product reviews program enables you to support fellow scientists by sharing your firsthand experience with our products.

No reviews yet

Aplidine

Description

Research Area

Images & Validation

Key Properties

Bioactivity

Storage & Handling

Alternative Names

Quality Guarantee

Compound Identifiers

Key Properties

Documents Download

Request a Document

Protocol Information

Aplidine (orb1297925)

Step 1: Enter information below

Step 2: Enter the in vivo formulation

Available Sizes

Email

UK Office

US Office

CN Office

Distributors